Scilex Holding Company · NASDAQ:SCLX
Scilex — Investor Presentation (May 2023)
35 slides from Scilex's investor presentation, May 2023
Slide 1: Innovative Leader in Non-Opioid Pain Therapeutics (May 2023)
Innovative Leader in Non-Opioid Pain Therapeutics (May 2023)
Slide 2: Safe Harbor Statements Forward-Looking Statements
Safe Harbor Statements Forward-Looking Statements Certain statements contained in this corporate presentation (this “Presentation”), along with certain statements that may be made by management of Scilex Holding Company (together with its subsidiaries, “Scilex”) orally in presenting this material, a
Slide 3: Executive Summary
HOLDING COMPANY Executive Summary
Slide 4: Company Background
Executive Summary Company Background Company Overview Corporate Timeline Scilex Holding Company (“Scilex”) is an innovative revenue-generating Feb. 2018: Scilex receives final pharmaceutical firm focused on developing and commercializing non- FDA approval for ZTlido™ opioid acute and chronic pain
Slide 5: Investment Highlights
Executive Summary Investment Highlights 1 3 FDA-approved Non-Opioid Acute and Chronic Pain Management Products 2 Worldwide Commercial Rights to Most Product Candidates 3 Strong Proprietary Platform with High Barriers to Entry 4 Established Reimbursement Access 5 Blockbuster Pipeline With Limited Cap
Slide 6: Innovative Non-Opioid Pain Therapeutics
Executive Summary Innovative Non-Opioid Pain Therapeutics KEY PROGRAMS PRECLINICAL PHASE 1 PHASE 2 PHASE 3 / PIVOTAL Phase 3 APPROVED IP MILESTONES / KEY COMMENTARY Platform Program IND Phase 1 Phase 2 NDA Approved Upcoming Milestones ZTlido® Pivotal (1.8% lidocaine topical system Approved for the t
Slide 7: ZTlido
ZTlido (1.8% lidocaine topical system equivalent to 5% lidocaine for the treatment of Postherpetic Neuralgia-PHN related pain)
Slide 8: ZTlido Sales Performance 2022-YTD23
ZTlido Sales Performance 2022-YTD23 April 2023 • Gross sales for April of 2023 were in the range of $9.5 million to $11.0 million, compared to $5.1 million in April of 2022, representing growth in the range of 86% to 116%. • Net sales for April of 2023 were in the range of $3.2 million to $4.0 milli
Slide 9: ZTlido Launched in USA 2018
ZTlido Launched inUSA 2018 see BIN NBN ¢ aiffing to Improve the World of Non-Opioid Management
Slide 10: ZTlido 1.8% (FDA approved for relief of PHN pain)
ZTlido® 1.8% (FDA approved for relief of PHN pain) 1 Lidocaine Patch Market Overview - +4.6mm prescriptions in 2022 - +169mm prescription lidocaine patches sold in the U.S. in 20221 2 Benefits versus Other Lidocaine Patches - Superior adhesion compared to other lidocaine patches head-to-head stu
Slide 11: ZTlido Market Access Update
ZTlido Market Access Update ZTlido Covered Lives Overview Key Players - Preference 350 308 21 ZTlido Preferred 300 69 250 218 State of California (MediCal) Lidocaine Preferred 200 150 ZTlido Preferred 100 50 62 ZTlido Preferred 0 Total Lives Later In-Negotiations Covered Negotiations 11
Slide 12: Historical Revenue Performance
Historical Revenue Performance ($ in millions) Q1-2022 Q2-2022 Q3-2022 Q4-2022 Q1-2023 Forecast TRXs (‘000) 67,908 83,090 90,696 94,857 94,855 Gross Sales $18.4 $21.0 $25.4 $31.3 $26.7 - $28.3 Net Sales $6.8 $7.9 $11.4 $11.9 $9.9 - $11.0 ~50% unit growth in Q1-2023, Sold ~214,000, units in 2021,
Slide 13: Elyxyb (celecoxib) oral solution (Acute Treatment of Migraine)
Elyxyb (celecoxib) oral solution (Acute Treatment of Migraine)
Slide 14: Elyxyb Launched in USA April 2023
Elyxyb Launched in USA April 2023 14
Slide 15: Market Overview and Value Proposition
Market Overview and Value Proposition ELYXYB™ has an opportunity to address unmet need for fast-acting acute migraine therapies as patients cycle through standard therapies • 39 million people suffer from migraines in the US, of which 9 million (23%) are on acute Rx therapies1 • US oral migraine mar
Slide 16: Elyxyb Promotion Materials
Elyxyb Promotion Materials 16
Slide 17: Gloperba
Gloperba (colchicine USP) oral solution (For the prevention of painful gout flares in adults)
Slide 18: Gloperba Launch in USA Planned in Q4 2023
Gloperba Launch in USA Planned in Q4 2023 18
Slide 19: Gloperba Launch Opportunity Overview
Gloperba Launch Opportunity Overview FDA Approved Gloperba • Gout is a painful arthritic disorder affecting over 8 million people in the United States.1 • 5.5 million patients experiencing with 2+ flares per year and requiring prophylactic therapy 2 • First line treatment for Gout includes colchicin
Slide 20: SP-102 (SEMDEXA) Treatment of Chronic Low Back Pain/Sciatica
SP-102 (SEMDEXA) Treatment of Chronic Low Back Pain/ Sciatica
Slide 21: Focus on Non-narcotic Pain Management Driving Growth
Focus on Non-narcotic Pain Management Driving Growth Prescription opioid abuse is at epidemic proportions in the U.S1 CURRENT PROBLEM Additionally, the CDC states that opioids do not provide clinically meaningful pain relief in patients with low back and chronic pain2 Multiple medical organiza
Slide 22: Epidural Steroid Injections (ESI) for Chronic Back Pain
Epidural Steroid Injections (ESI) for Chronic Back Pain One of the Most Common Medical Procedures / Top Pain Procedures Strong Growth Rate, Evidenced by Medicare Procedure Volumes (MM) Medicare Overall ESI Injection Volume1 14 1 ESIs widely reimbursed as procedure to delay or avoid back surgery 12
Slide 23: On-Track as First Epidural Steroid Injection with a Label to Treat Sciatica
On-Track as First Epidural Steroid Injection with a Label to Treat Sciatica SP-102 (SEMDEXA) is a preservative free, surfactant free and particulate free viscous gel formulation of well known corticosteroid for sciatica (subacute lumbosacral radicular pain). Extended local effect provides durable pa
Slide 24: Phase III C.L.E.A.R. Trial Met Primary Endpoint
Phase III C.L.E.A.R. Trial Met Primary Endpoint Phase III Primary Endpoint Overview Phase III SP-102 C.L.E.A.R Trial – Primary Endpoint Change in Average Daily Pain in Affected Leg The trial met primary, key secondary and other Numeric Pain Rating Scale, LS Mean 0 secondary endpoints with statistica
Slide 25: C.L.E.A.R. Trial – Key Secondary Endpoint
C.L.E.A.R. Trial – Key Secondary Endpoint Phase III Secondary Endpoint Overview Phase III SP-102 C.L.E.A.R Trial – Secondary Endpoint The Oswestry Disability Index (ODI) - gold standard Oswestry Disability Index Percentage for measuring degree of disability and estimating Change from Baseline at Wee
Slide 26: C.L.E.A.R. Trial – Effect Duration and Safety
C.L.E.A.R. Trial – Effect Duration and Safety SP-102 Time to Repeat Injection (Return of Moderate-Severe Pain) Month 1 Month 2 Month 3 Month 4 Month 5 Primary Endpoint Allowance for Open-Label Repeat Injection of SP-102 SP-102 (SEMDEXA™) showed continued reduction of pain beyond one month, and the m
Slide 27: Phase III SP-102 C.L.E.A.R. Trial – Conclusions and Summary
Phase III SP-102 C.L.E.A.R. Trial – Conclusions and Summary This is the largest prospective, randomized, double-blind, placebo-controlled study testing the effect and safety of a corticosteroid SP-102 showed meaningful pain relief with significantly large differences relative to placebo (p<0.001) fo
Slide 28: SP-103 (5.4%, 3X lidocaine topical system) for Treatment of Acute Back Pain
SP-103 (5.4%, 3X lidocaine topical system) for Treatment of Acute Back Pain
Slide 29: SP-103 Phase 2
Next-Generation, Triple Strength Formulation of ZTlido 1.8% SP-103 Phase 2 Next-Generation, 5.4% Lidocaine Topical System 3x drug load (108 mg vs 36 mg lidocaine) Superior adhesion and drug formulation Triple strength localized dose of lidocaine efficiency with only 36mg of lidocaine Expecte
Slide 30: Phase II Trial Summary
Phase II Trial Summary Phase II, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower back pain. Subjects are expected to apply investigational product for 12 hours per study
Slide 31: SP-104
SP-104
Slide 32: Delayed Burst Low Dose Naltrexone (LDN) – Fibromyalgia
Delayed Burst Low Dose Naltrexone (LDN) – Fibromyalgia Fibromyalgia is a long-term condition that causes pain all over the body and affects 3% to 6% of the world population (an estimated 10 million people in the U.S., 75-90% women)1 Low Dose Naltrexone (LDN) efficacy well documented Routinely used o
Slide 33: Management
HOLDING COMPANY Management
Slide 34: Infrastructure Overview Management Team
Infrastructure Overview Management Team Jaisim Shah Elizabeth Czerepak Dmitri Lissin, MD Steve Lincoln Chief Executive & President Chief Financial Officer & Chief Chief Medical Officer GC and Chief Compliance Officer Business Officer 25+ years of management 35+ years of finance, business 20+ y
Slide 35: Nasdaq (November 11, 2022)
Nasdaq (November 11, 2022) 35
Scilex Holding Company — Investor Presentation (May 2023) on 6ix